Format

Send to

Choose Destination
J Surg Oncol. 2012 Dec;106(7):911-7. doi: 10.1002/jso.23146. Epub 2012 May 14.

Mucin as a therapeutic target in pseudomyxoma peritonei.

Author information

1
Division of Surgical Oncology, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania 15261, USA. choudrymh@upmc.edu

Abstract

Pseudomyxoma peritonei (PMP) is characterized by intraperitoneal dissemination of mucinous ascites. This malignancy frequently recurs despite aggressive locoregional therapies, demonstrates chemo-insensitivity and lacks targeted therapies. This review addresses some intriguing questions in PMP; what role does mucin play in this malignancy?; what genetic alterations and dysregulated signaling pathways lead to a putative goblet cell-lineage differentiation or mucin overexpression?; are targeted therapies against known transcriptional pathways for mucin production a novel therapeutic strategy in this malignancy?

PMID:
22585683
DOI:
10.1002/jso.23146
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Wiley
Loading ...
Support Center